{
    "clinical_study": {
        "@rank": "43401", 
        "arm_group": {
            "arm_group_label": "Ranolazine", 
            "arm_group_type": "Experimental", 
            "description": "Ranolazine 500-1000 mg twice a day as tolerated"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether ranolazine will reduce the risk of\n      arrhythmic events in patients with long QT syndrome type 3."
        }, 
        "brief_title": "Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine", 
        "completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Long QT Syndrome Type 3", 
        "condition_browse": {
            "mesh_term": "Long QT Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Long QT patients with genetic confirmation of carrier-status for the D1790G mutation\n             in the SCN5A gene\n\n          -  Corrected QT interval > 460 msec\n\n        Exclusion Criteria:\n\n          -  Need for therapy with medications that are potent or moderately potent CYP3A\n             inhibitors (such as ketoconazole, diltiazem, verapamil, macrolide antibiotics or HIV\n             protease inhibitors)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728025", 
            "org_study_id": "TASMC-12-SV-0363-10-CTIL"
        }, 
        "intervention": {
            "arm_group_label": "Ranolazine", 
            "intervention_name": "Ranolazine", 
            "intervention_type": "Drug", 
            "other_name": "Ranexa"
        }, 
        "intervention_browse": {
            "mesh_term": "Ranolazine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Long QT syndrome", 
            "Ranolazine"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "contact": {
                "email": "samiviskin@gmail.com", 
                "last_name": "Sami Viskin, MD", 
                "phone": "972-3-6973311"
            }, 
            "facility": {
                "address": {
                    "city": "Tel Aviv", 
                    "country": "Israel"
                }, 
                "name": "Tel Aviv Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Sami Viskin, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jesaia Benhorin, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Arnon Adler, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "samiviskin@gmail.com", 
            "last_name": "Sami Viskin, MD", 
            "phone": "972-3-6973311"
        }, 
        "overall_contact_backup": {
            "last_name": "Jesaia Benhorin, MD", 
            "phone": "972-3-6973311"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with syncope and/or documented ventricular arrhythmia", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "reference": [
            {
                "PMID": "18662191", 
                "citation": "Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008 Dec;19(12):1289-93. Epub 2008 Jul 25."
            }, 
            {
                "PMID": "19371746", 
                "citation": "Lindegger N, Hagen BM, Marks AR, Lederer WJ, Kass RS. Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine. J Mol Cell Cardiol. 2009 Aug;47(2):326-34. Epub 2009 Apr 14."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728025"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in corrected QT interval", 
            "safety_issue": "Yes", 
            "time_frame": "within 30 days of initiation of Ranolazine treatment"
        }, 
        "source": "Tel-Aviv Sourasky Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tel-Aviv Sourasky Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}